Nanjing Leads Biolabs' Public Offering Stabilization Period Ends
MT Newswires Live
Aug 22
Nanjing Leads Biolabs (HKG:9887) said the stabilization period of its Hong Kong listing ended on Thursday, Aug. 21, according to a same-day Hong Kong bourse filing.
Shares of the company closed 4% lower on Friday.
The IPO's stabilizing manager overallocated 12,821,700 H shares in the international portion of the offering, while underwriters fully exercised their overallotment option to purchase 5,529,300 shares.
No H shares were sold or purchased on the market during the stabilization period, the company said.
The biotech company said its public float continues to comply with Hong Kong's listing requirements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.